XML 49 R38.htm IDEA: XBRL DOCUMENT v3.25.3
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 24 Months Ended
Sep. 28, 2025
Sep. 29, 2024
Sep. 28, 2025
Sep. 29, 2024
Sep. 28, 2025
Restructuring Cost and Reserve [Line Items]          
Restructuring charges [1] $ 237 $ 217 $ 784 $ 1,331  
Productivity and Operational Efficiencies [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring charges     96    
Biopharma [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring charges 240 $ 141 451 1,200  
Realigning Our Cost Base Program [Member]          
Restructuring Cost and Reserve [Line Items]          
Expected restructuring cost 5,300   5,300   $ 5,300
Restructuring cost incurred to date 3,700   3,700   3,700
Realigning Our Cost Base Program [Member] | Biopharma [Member]          
Restructuring Cost and Reserve [Line Items]          
Expected restructuring cost 3,700   3,700   3,700
Restructuring cost incurred to date 2,900   2,900   2,900
Restructuring charges 107   669 (69) 2,600
Realigning Our Cost Base Program - Initial Phase [Member]          
Restructuring Cost and Reserve [Line Items]          
Expected restructuring cost 4,700   4,700   4,700
Realigning Our Cost Base Program - Initial Phase [Member] | Biopharma [Member]          
Restructuring Cost and Reserve [Line Items]          
Expected restructuring cost 3,100   3,100   3,100
Realigning Our Cost Base Program - Research and Development [Member] | Biopharma [Member] | Productivity and Operational Efficiencies [Member]          
Restructuring Cost and Reserve [Line Items]          
Expected restructuring cost 600   600   600
Manufacturing Optimization Program [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring cost incurred to date 1,000   1,000   1,000
Manufacturing Optimization Program [Member] | Biopharma [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring charges 117   (295) $ 1,300  
Manufacturing Optimization Program - Phase One [Member] | Biopharma [Member]          
Restructuring Cost and Reserve [Line Items]          
Expected restructuring cost $ 1,400   $ 1,400   $ 1,400
[1] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $240 million for the three months ended September 28, 2025 (including charges of $117 million for our Manufacturing Optimization Program and charges of $107 million for our Realigning our Cost Base Program), (ii) charges of $451 million for the nine months ended September 28, 2025 (including charges of $669 million for our Realigning our Cost Base Program and credits of $295 million for our Manufacturing Optimization Program), (iii) charges of $141 million for the three months ended September 29, 2024 (primarily including charges for our Realigning our Cost Base Program) and (iv) charges of $1.2 billion for the nine months ended September 29, 2024 (including charges of $1.3 billion for our Manufacturing Optimization Program and credits of $69 million for our Realigning our Cost
Base Program). For the nine months ended September 28, 2025 and September 29, 2024, Employee terminations include revisions of estimates of previously recorded accruals for severance benefits, driven in large part by higher-than-expected voluntary attrition.